Fundraising Fox

Alexza Pharmaceuticals

Mountain View, US · Founded 2000 · 82 employees on LinkedIn · 2 known investors

Alexza Pharmaceuticals, now operating as Nova Pneuma, Inc., is a pharmaceutical company that developed the Staccato One Breath Technology drug-delivery platform and markets the commercial product Adasuve. Its Staccato platform and assets were acquired by Lee's Pharmaceutical Holdings.

BiotechHealthtech

Founders & leadership

ES
Edwin S KamemotoExecutive
MK
Mark K OkiExecutive
TB
Thomas B KingExecutive
MJ
Michael J SimmsExecutive
JV
James V CassellaExecutive
RA
Robert A LippeExecutive

Board

IS
Isaac SteinBoard director
JL
J Leighton ReadBoard director
DR
Deepika R PakianathanBoard director
SD
Samuel D. ColellaBoard director
AL
Andrew L BusserBoard director
JK
J Kevin BuchiBoard director

Investors · 2

5AM VenturesBoston · $100K – $4M
New Enterprise Associates (NEA)Menlo Park · $200K – $40M

Reported raises · per SEC filings

Form D private placements

$16.1M disclosed across 5 rounds · 2012–2016

▶$5MraisedFeb 2016 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Isaac SteinDirector
  • Deepika R PakianathanDirector
  • Joseph L TurnerDirector
  • Thomas B KingExecutive Officer, Director
  • J Leighton ReadDirector
  • Gordon RingoldDirector
  • Edwin S KamemotoExecutive Officer
  • J Kevin BuchiDirector
Offering amount
$5M
Amount sold
$5M
First sale
Feb 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$143.8KraisedSep 2015 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Edwin S KamemotoExecutive Officer
  • Mark K OkiExecutive Officer
  • Isaac SteinDirector
  • J Kevin BuchiDirector
  • J Leighton ReadDirector
  • Thomas B KingExecutive Officer, Director
  • Deepika R PakianathanDirector
  • Gordon RingoldDirector
  • Joseph L TurnerDirector
Offering amount
$143.8K
Amount sold
$143.8K
First sale
Sep 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8MraisedOct 2014 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark K OkiExecutive Officer
  • Robert A LippeExecutive Officer
  • Gordon RingoldDirector
  • Isaac SteinDirector
  • James V CassellaExecutive Officer
  • Joseph L TurnerDirector
  • Deepika R PakianathanDirector
  • Edwin S KamemotoExecutive Officer
  • Thomas B KingExecutive Officer, Director
  • J Leighton ReadDirector
  • J Kevin BuchiDirector
Offering amount
$8M
Amount sold
$8M
First sale
Oct 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.5KraisedMar 2014 · 9 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Gordon RingoldDirector
  • J Leighton ReadDirector
  • James V CassellaExecutive Officer
  • Robert A. LippeExecutive Officer
  • Michael J SimmsExecutive Officer
  • Thomas B KingExecutive Officer, Director
  • Deepika R PakianathanDirector
  • Mark K OkiExecutive Officer
  • J Kevin BuchiDirector
  • Isaac SteinDirector
  • Joseph L. TurnerDirector
Offering amount
$3.5K
Amount sold
$3.5K
Sales commissions
$240
Placement agents
Morgan Stanley & Co. LLC
First sale
Mar 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3MraisedMar 2012 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Joseph L TurnerDirector
  • Thomas B KingExecutive Officer, Director
  • Michael J SimmsExecutive Officer
  • James V CassellaExecutive Officer
  • Mark K OkiExecutive Officer
  • Deepika R PakianathanDirector
  • Isaac SteinDirector
  • Hal V BarronDirector
  • Samuel D. ColellaDirector
  • J Leighton ReadDirector
  • Andrew L BusserDirector
  • Gordon RingoldDirector
Offering amount
$3M
Amount sold
$3M
First sale
Mar 2012
Incorporated
Corporation, Delaware
Federal exemptions
06
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Alexza Pharmaceuticals do?
Alexza Pharmaceuticals, now operating as Nova Pneuma, Inc., is a pharmaceutical company that developed the Staccato One Breath Technology drug-delivery platform and markets the commercial product Adasuve. Its Staccato platform and assets were acquired by Lee's Pharmaceutical Holdings.
Who are Alexza Pharmaceuticals's investors?
Alexza Pharmaceuticals's investors include 5AM Ventures, New Enterprise Associates (NEA).
How much funding has Alexza Pharmaceuticals raised?
Alexza Pharmaceuticals has disclosed $16.1M raised across 5 rounds.
Where is Alexza Pharmaceuticals headquartered?
Alexza Pharmaceuticals is headquartered in Mountain View, US.